Mizuho Securities Co. Ltd. Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Mizuho Securities Co. Ltd. lowered its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 24.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,555 shares of the company’s stock after selling 509 shares during the period. Mizuho Securities Co. Ltd.’s holdings in Johnson & Johnson were worth $254,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. RKL Wealth Management LLC raised its stake in shares of Johnson & Johnson by 2.1% in the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after acquiring an additional 1,010 shares during the period. Geller Advisors LLC grew its holdings in Johnson & Johnson by 7.5% during the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after purchasing an additional 648 shares in the last quarter. Simon Quick Advisors LLC grew its holdings in Johnson & Johnson by 296.9% during the 2nd quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after purchasing an additional 6,537 shares in the last quarter. Lokken Investment Group LLC grew its holdings in Johnson & Johnson by 1.6% during the 2nd quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after purchasing an additional 201 shares in the last quarter. Finally, Keebeck Alpha LP grew its holdings in Johnson & Johnson by 13.4% during the 2nd quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock valued at $788,000 after purchasing an additional 525 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a 50-day simple moving average of $175.98 and a 200-day simple moving average of $171.06. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The firm has a market capitalization of $440.04 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.12. The firm had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the firm posted $2.13 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Insider Activity at Johnson & Johnson

In related news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock worth $40,960,735 in the last ninety days. 0.35% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Citigroup raised their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Atlantic Securities decreased their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Finally, Bank of America decreased their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.